PLx Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PLx Pharma Inc.
Sustainability claims are growing as targets of reviews by BBB National Programs investigative divisions, which also anticipate more ad violations from online dark patterns in 2022.
BBB National Programs’ appeals panel agrees with National Advertising Division that PLx should modify TV ad to clearly and conspicuously disclose that “clinically shown to cause fewer ulcers than plain aspirin” refers to Vazalore 325 mg and not 81-mg dose.
Over past year, PLx's Vazalore ad claimswere reviewed National Advertising Division before and after launch. As PLx appeals NAD’s post-launch review findings, NAD attorneys send questions about pre-launch claims to FTC.
PLx disagrees with National Advertising Division’s recommendations following review on Bayer’s challenge of TV commercial and will appeal findings to National Advertising Review Board. NAD attorneys thank PLx’s “ voluntary participation” in SWIFT review but PLx makes clear it didn’t agree to a SWIFT process.
- Drug Delivery
- OTC, Consumer
- Other Names / Subsidiaries
- Dipexium Pharmaceuticals, LLC
- PLx Opco Inc
- PLx Chile SpA.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.